Table 2.
Treatment and medical history
| Characteristic | Patients (N = 202) |
|---|---|
| Time since NET diagnosis,a mean (SD) years | 6.9 (5.0) |
| Diagnosed with CS or experienced CS-related symptoms, n (%) | 181 (89.6) |
| Type of LA SSA injection currently receiving, n (%) | |
| Somatuline depot (lanreotide) | 82 (40.6) |
| Sandostatin LAR (octreotide) | 120 (59.4) |
| Length of time receiving current injection, n (%) | |
| Less than a year | 44 (21.8) |
| 1 to < 5 years | 98 (48.5) |
| 5 to < 8 years | 32 (15.8) |
| 8 years or more | 28 (13.9) |
| Experience receiving lanreotide and octreotide, n (%)b | 41 (20.3) |
| Location of most recent injection, n (%) | |
| Community (nonacademic) clinic/office/treatment center | 101 (50.0) |
| Academic or university-associated clinic/office/treatment center | 85 (42.1) |
| At home by a visiting nurse | 5 (2.5) |
| Other | 10 (5.0) |
| Don’t know/not sure | 1 (0.5) |
| Primary location of NET, n (%) | |
| Gastrointestinalc | 137 (67.8) |
| Unknown primary sited | 21 (10.4) |
| Lung | 17 (8.4) |
| Pancreas | 12 (5.9) |
| Livere | 3 (1.5) |
| Kidney | 2 (1.0) |
| Ovary | 1 (0.5) |
| Other | 7 (3.5) |
| Don’t know/don’t remember | 2 (1.0) |
CS Carcinoid syndrome, LA SSA long-acting somatostatin analog, LAR long-acting release, NET neuroendocrine tumors; SD standard deviation
aN = 200
bRespondents were asked whether they had ever received octreotide and ever received lanreotide; 41 respondents had received both types of LA SSA
cIncludes appendix (n = 8), large intestine (colon, large bowel) (n = 13), small intestine (small bowel, duodenum, jejunum, ileum) (n = 109), stomach (n = 5), and rectum (n = 2)
dThe primary tumor site was unknown to the physician at diagnosis
ePrimary NETs of the liver are extremely rare, and respondents with metastatic disease to the liver may have reported their tumors as being primary to the liver. Metastatic disease to the liver cannot be ruled out for these responses